Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Drops By 38.8%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a significant drop in short interest in May. As of May 15th, there was short interest totalling 221,700 shares, a drop of 38.8% from the April 30th total of 362,300 shares. Approximately 4.7% of the shares of the stock are short sold. Based on an average trading volume of 3,410,000 shares, the days-to-cover ratio is presently 0.1 days.

Hedge Funds Weigh In On ZyVersa Therapeutics

An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Virtu Financial LLC acquired a new position in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned approximately 1.08% of ZyVersa Therapeutics as of its most recent filing with the Securities & Exchange Commission. 3.91% of the stock is owned by hedge funds and other institutional investors.

ZyVersa Therapeutics Stock Performance

NASDAQ ZVSA opened at $0.65 on Monday. ZyVersa Therapeutics has a 1-year low of $0.47 and a 1-year high of $6.30. The stock’s 50 day simple moving average is $0.67 and its 200-day simple moving average is $0.98.

ZyVersa Therapeutics (NASDAQ:ZVSA) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.33). As a group, sell-side analysts forecast that ZyVersa Therapeutics will post -22.7 EPS for the current year.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.